Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million– Following ...

Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Equals 5, the leading AdTech platform revolutionizing pharmaceutical and healthcare marketing is excited to announce a strategic growth equity investment from Baleon Capital. This investment marks a ...

This article discusses the Anti-Kickback Statute and the False Claims Act. "When coupled with the False Claims Act (FCA), the AKS turns into a potent civil enforcement tool that carries many of the ...

Pharmaceutical company Takeda is pioneering a technology-enabled, patient-centered future for plasma-derived therapies ...

Samsung Biologics (KRX: 207940.KS), a global contract manufacturing and development organization (CDMO), today announced that ...

Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...

The World Health Organization (WHO) and St. Jude Children's Research Hospital have commenced distribution of critically-needed childhood cancer medicines in 2 of 6 pilot countries, through the Global ...

"The addition of this five-partner team extends the capabilities of our 200-plus lawyer IP team," Morgan Lewis’ global IP ...

One of the pillars of modern medicine is the life-saving drugs that pharmaceutical companies spend years developing to cure and prevent diseases. But what if th ...